Presentation is loading. Please wait.

Presentation is loading. Please wait.

MOBILE Trial design: Patients with critical limb ischemia were randomized to intramuscular injection of bone marrow-derived stem cells (n = 119) vs. placebo.

Published byAugust Maxwell Modified over 5 years ago

Similar presentations

Presentation on theme: "MOBILE Trial design: Patients with critical limb ischemia were randomized to intramuscular injection of bone marrow-derived stem cells (n = 119) vs. placebo."— Presentation transcript:

1 MOBILE Trial design: Patients with critical limb ischemia were randomized to intramuscular injection of bone marrow-derived stem cells (n = 119) vs. placebo injection (n = 36). (p = 0.33) Results Serious adverse events: 59% of the stem cell group vs. 69% of the placebo group (p = 0.33) Death or amputation: 20% of the stem cell group vs. 31% of the placebo group (p = 0.22) 69 59 % Conclusions Among patients with critical limb ischemia, intramuscular injection of bone marrow-derived stem cells was feasible This small pilot study demonstrated the safety of stem cell injection Stem cell Placebo Presented by Dr. Michael P. Murphy at AHA 2016

Download ppt "MOBILE Trial design: Patients with critical limb ischemia were randomized to intramuscular injection of bone marrow-derived stem cells (n = 119) vs. placebo."

Similar presentations

What is REGENERATIVE MEDICINE? “The regeneration or replacement of cells, tissues or organs to restore or establish normal function.” The goal is to.

What is REGENERATIVE MEDICINE? “The regeneration or replacement of cells, tissues or organs to restore or establish normal function.” The goal is to.
{ R. Diaz-Garcia MD, J. Bernardo MD Stem Cell Therapy for Patients with Critical Limb Ischemia: A Meta-analysis with Critical Limb Ischemia: A Meta-analysis.

{ R. Diaz-Garcia MD, J. Bernardo MD Stem Cell Therapy for Patients with Critical Limb Ischemia: A Meta-analysis with Critical Limb Ischemia: A Meta-analysis.
Limbs International Medical Buflomedil Trial Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Alain Leizorovicz LIMB.

Limbs International Medical Buflomedil Trial Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Alain Leizorovicz LIMB.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.

EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
(p for noninferiority = 0.01)

(p for noninferiority = 0.01)
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
Copyright © 2009 American Medical Association. All rights reserved.

Copyright © 2009 American Medical Association. All rights reserved.
Fig 1: Microscopic Spindle shaped MSCs Fig 2: Method of MSCs Injection

Fig 1: Microscopic Spindle shaped MSCs Fig 2: Method of MSCs Injection
Harrison CN et al. Proc ASH 2015;Abstract 59.

Harrison CN et al. Proc ASH 2015;Abstract 59.
RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.
IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.

IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.
BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for 40-80 days.

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.
Phase 2 Treatment Naïve Injection Drug Use

Phase 2 Treatment Naïve Injection Drug Use
AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.
ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.
DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)

DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.
TECAM Trial design: STEMI patients who underwent successful reperfusion therapy were randomized on day 1 to intracoronary bone marrow autologous mononuclear.

TECAM Trial design: STEMI patients who underwent successful reperfusion therapy were randomized on day 1 to intracoronary bone marrow autologous mononuclear.
Autologous bone marrow mononuclear cell therapy is safe and promotes amputation- free survival in patients with critical limb ischemia  Michael P. Murphy,

Autologous bone marrow mononuclear cell therapy is safe and promotes amputation- free survival in patients with critical limb ischemia  Michael P. Murphy,

Similar presentations

Ads by Google